A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.
Zefei Jiang, Hua Yang(Affiliated Hospital of Hebei University), Wuyun Su(Inner Mongolia Medical University), Guohua Yu(Qingdao University), Yueyin Pan(Anhui Provincial Hospital), Yongmei Yin(Nanjing Medical University), Min Yan(Shanxi Agricultural University), Zhongsheng Tong(Institute of Oncology NN Petrov), Qiang Liu(Sun Yat-sen University), Cuizhi Geng(Hebei Medical University), Shusen Wang(Sun Yat-sen University), Xiaojia Wang(Wenzhou Medical University), Jingfen Wang, Jinhai Tang(Nanjing University of Chinese Medicine), Tao Sun(Shandong Provincial Hospital)
Cited by 36
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k